These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36683866)

  • 81. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Revision of serum ALT upper limits of normal facilitates assessment of mild liver injury in obese children with non-alcoholic fatty liver disease.
    Lu Y; Wang Q; Yu L; Yin X; Yang H; Xu X; Xia Y; Luo Y; Peng Y; Yu Q; Chen Z; Yu J; Lai M; Wu N; Pan XB; Zheng X
    J Clin Lab Anal; 2020 Jul; 34(7):e23285. PubMed ID: 32267017
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease.
    Iritani S; Akuta N; Kawamura Y; Kajiwara A; Kasuya K; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saito S; Suzuki F; Arase Y; Ikeda K; Suzuki Y; Kumada H
    BMC Gastroenterol; 2020 Nov; 20(1):368. PubMed ID: 33148171
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Editorial: "Lean" NAFLD: Metabolic Obesity with Normal BMI… Is It in the Genes?
    Argo CK; Henry ZH
    Am J Gastroenterol; 2017 Jan; 112(1):111-113. PubMed ID: 28050048
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model.
    Ohkoshi-Yamada M; Kamimura K; Kimura A; Tanaka Y; Nagayama I; Yakubo S; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
    Biochem Biophys Res Commun; 2022 Oct; 625():116-121. PubMed ID: 35952608
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
    Navarroza AMC; Wong SN
    Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.
    Niriella MA; Kasturiratne A; Pathmeswaran A; De Silva ST; Perera KR; Subasinghe SKCE; Kodisinghe SK; Piyaratna TACL; Vithiya K; Dassanayaka AS; De Silva AP; Wickramasinghe AR; Takeuchi F; Kato N; de Silva HJ
    Hepatol Int; 2019 May; 13(3):314-322. PubMed ID: 30539516
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
    Cuthbertson DJ; Koskinen J; Brown E; Magnussen CG; Hutri-Kähönen N; Sabin M; Tossavainen P; Jokinen E; Laitinen T; Viikari J; Raitakari OT; Juonala M
    Ann Med; 2021 Dec; 53(1):1256-1264. PubMed ID: 34309471
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.
    Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai RK; Dasarathy S; McCullough AJ
    BBA Clin; 2015 Jun; 3():141-5. PubMed ID: 26675585
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.
    Hamurcu Varol P; Kaya E; Alphan E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1352-1357. PubMed ID: 32092046
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
    Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
    JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery.
    Jamialahmadi T; Nematy M; Jangjoo A; Goshayeshi L; Abdalla MA; Akhlaghi S; Sathyapalan T; Sahebkar A
    Eat Weight Disord; 2022 Mar; 27(2):693-700. PubMed ID: 33999371
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia.
    Khayyat YM
    World J Hepatol; 2021 Dec; 13(12):2150-2160. PubMed ID: 35070015
    [TBL] [Abstract][Full Text] [Related]  

  • 98. (
    Molina-Molina E; Shanmugam H; Di Ciaula A; Grattagliano I; Di Palo DM; Palmieri VO; Portincasa P
    JHEP Rep; 2021 Feb; 3(1):100203. PubMed ID: 33490935
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity.
    Sinha N; Mukhopadhyay S; Sau M
    Indian J Gastroenterol; 2020 Feb; 39(1):75-83. PubMed ID: 32314167
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease.
    Imamura T; Kinugawa K
    Intern Med; 2023 May; 62(9):1371-1373. PubMed ID: 36198591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.